{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:00:27Z","timestamp":1762506027130},"reference-count":61,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Joint Bone Spine"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1016\/j.jbspin.2012.10.023","type":"journal-article","created":{"date-parts":[[2012,12,11]],"date-time":"2012-12-11T03:47:34Z","timestamp":1355197654000},"page":"374-379","source":"Crossref","is-referenced-by-count":13,"title":["Therapeutic immunomodulation in systemic vasculitis: Taking stock"],"prefix":"10.1016","volume":"80","author":[{"given":"Xavier","family":"Pu\u00e9chal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lo\u00efc","family":"Guillevin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbspin.2012.10.023_bib0005","doi-asserted-by":"crossref","unstructured":"Jennette JC, Falk RJ, Bacon PA, et al. Revised International Chapel Hill Consensus Conference Nomenclature of the Vasculitides. Arthritis Rheum 2012. doi:10.1002\/art.37715 [Epub ahead of print].","DOI":"10.1002\/art.37715"},{"key":"10.1016\/j.jbspin.2012.10.023_bib0015","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2012.10.023_bib0020","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2012.10.023_bib0025","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jaut.2010.09.002","article-title":"Wegener's granuloma harbors B lymphocytes with specificities against a proinflammatory transmembrane protein and a tetraspanin","volume":"36","author":"Thurner","year":"2011","journal-title":"J Autoimmun"},{"key":"10.1016\/j.jbspin.2012.10.023_bib0320","first-page":"S706","article-title":"Rituximab versus azathioprine for maintenance in antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (abstract)","volume":"64","author":"Guillevin","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2012.10.023_bib0035","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1093\/rheumatology\/ker150","article-title":"Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis","volume":"51","author":"Guerry","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2012.10.023_bib0045","doi-asserted-by":"crossref","unstructured":"Smith RM, Jones RB, Guerry MJ, et al. Rituximab for remission maintenance in relapsing ANCA-associated vasculitis. Arthritis Rheum 2012; doi:10.1002\/art.34583 [Epub ahead of print].","DOI":"10.1002\/art.34583"},{"key":"10.1016\/j.jbspin.2012.10.023_bib0050","doi-asserted-by":"crossref","unstructured":"Cartin-Ceba R, Golbin JM, Keogh KA, et al. Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): A single-center ten-year experience. Arthritis Rheum 2012; doi:10.1002\/art.34584 [Epub ahead of print].","DOI":"10.1002\/art.34584"},{"key":"10.1016\/j.jbspin.2012.10.023_bib0055","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1002\/art.34468","article-title":"Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies","volume":"64","author":"Molloy","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2012.10.023_bib0060","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jbspin.2011.11.002","article-title":"Progressive multifocal leukoencephalopathy in autoimmune diseases","volume":"79","author":"Palazzo","year":"2012","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2012.10.023_bib0065","doi-asserted-by":"crossref","first-page":"iv31","DOI":"10.1136\/ard.2005.042416","article-title":"Current state of tumour necrosis factor alpha blockade in Wegener's granulomatosis","volume":"64","author":"Mukhtyar","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2012.10.023_bib0070","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1093\/rheumatology\/41.10.1126","article-title":"Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients","volume":"41","author":"Bartolucci","year":"2002","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2012.10.023_bib0075","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1097\/01.ASN.0000114554.67106.28","article-title":"Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis","volume":"15","author":"Booth","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jbspin.2012.10.023_bib0080","first-page":"S63","article-title":"Infliximab or rituximab for refractory Wegener's granulomatosis: long-term follow-up. A prospective randomised multicentre study on 17 patients","volume":"29","author":"de Menthon","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jbspin.2012.10.023_bib0085","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa041884","article-title":"Etanercept plus standard therapy for Wegener's granulomatosis","volume":"352","author":"The Wegener's Granulomatosis Etanercept Trial (WGET) Research Group","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2012.10.023_bib0090","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/qjmed\/93.7.433","article-title":"Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity","volume":"93","author":"Jayne","year":"2000","journal-title":"Q J Med"},{"key":"10.1016\/j.jbspin.2012.10.023_bib0095","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/art.23147","article-title":"Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients","volume":"58","author":"Martinez","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2012.10.023_bib0100","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1681\/ASN.2007010090","article-title":"Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis","volume":"18","author":"Jayne","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jbspin.2012.10.023_bib0105","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1016\/0140-6736(93)90759-A","article-title":"Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy","volume":"1","author":"Lockwood","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.jbspin.2012.10.023_bib0110","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1136\/ard.2007.081661","article-title":"Long-term follow-up of relapsing\/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (Campath-1H)","volume":"67","author":"Walsh","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2012.10.023_bib0115","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1136\/ard.2008.093773","article-title":"Severe bronchospasm associated with rituximab for refractory Churg-Strauss syndrome","volume":"68","author":"Bouldouyre","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2012.10.023_bib0120","first-page":"S35","article-title":"A phase II study of interferon-alpha for the treatment of refractory Churg-Strauss syndrome","volume":"26","author":"Metzler","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jbspin.2012.10.023_bib0125","first-page":"24","article-title":"Interferon-alpha for maintenance of remission in Churg-Strauss syndrome: a long-term observational study","volume":"28","author":"Metzler","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jbspin.2012.10.023_bib0130","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/j.jaci.2010.03.028","article-title":"Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome","volume":"125","author":"Kim","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jbspin.2012.10.023_bib0135","doi-asserted-by":"crossref","first-page":"341","DOI":"10.7326\/0003-4819-155-5-201109060-00026","article-title":"Targeting interleukin-5 in refractory and relapsing Churg-Strauss syndrome","volume":"155","author":"Moosig","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jbspin.2012.10.023_bib0140","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/art.34331","article-title":"A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis","volume":"64","author":"De Vita","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2012.10.023_bib0145","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1002\/art.34322","article-title":"A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis","volume":"64","author":"Sneller","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2012.10.023_bib0150","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.autrev.2011.01.008","article-title":"Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients","volume":"10","author":"Petrogrande","year":"2011","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jbspin.2012.10.023_bib0155","doi-asserted-by":"crossref","first-page":"3848","DOI":"10.1002\/art.25000","article-title":"Rituximab may form a complex with IgMkappa mixed cryoglobulin and induce severe systemic reactions in patients with hepatitis C virus-induced vasculitis","volume":"60","author":"S\u00e8ne","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2012.10.023_bib0160","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1056\/NEJMoa1105143","article-title":"Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis","volume":"365","author":"Saadoun","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2012.10.023_bib0165","first-page":"289","article-title":"Treatment of polyarteritis nodosa related to hepatitis B virus with short-term steroid therapy associated with antiviral agents and plasma exchanges. A prospective trial in 33 patients","volume":"20","author":"Guillevin","year":"1993","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2012.10.023_bib0170","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1136\/ard.53.5.334","article-title":"Treatment of polyarteritis nodosa related to hepatitis B virus with interferon-alpha and plasma exchanges","volume":"53","author":"Guillevin","year":"1994","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2012.10.023_bib0175","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/00005792-199509000-00002","article-title":"Polyarteritis nodosa related to hepatitis B virus. A prospective study with long-term observation of 41 patients","volume":"74","author":"Guillevin","year":"1995","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jbspin.2012.10.023_bib0180","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1002\/art.20401","article-title":"Short-term corticosteroids then lamivudine and plasma exchanges to treat hepatitis B virus-related polyarteritis nodosa","volume":"51","author":"Guillevin","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2012.10.023_bib0185","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/acr.20381","article-title":"Hepatitis C virus-associated polyarteritis nodosa","volume":"63","author":"Saadoun","year":"2011","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.jbspin.2012.10.023_bib0190","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1056\/NEJM200105103441919","article-title":"Treatment of parvovirus B19-associated polyarteritis nodosa with intravenous immune globulins","volume":"344","author":"Viguier","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2012.10.023_bib0195","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJM198608073150601","article-title":"The treatment of Kawasaki syndrome with intravenous gamma globulin","volume":"315","author":"Newburger","year":"1986","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2012.10.023_bib0200","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1056\/NEJM199106063242305","article-title":"A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome","volume":"324","author":"Newburger","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2012.10.023_bib0205","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/S0140-6736(12)60196-2","article-title":"Management of Kawasaki disease: corticosteroids revisited","volume":"379","author":"Son","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jbspin.2012.10.023_bib0210","doi-asserted-by":"crossref","first-page":"621","DOI":"10.7326\/0003-4819-146-9-200705010-00004","article-title":"Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial","volume":"146","author":"Hoffman","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jbspin.2012.10.023_bib0215","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1136\/ard.2007.082115","article-title":"A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects","volume":"67","author":"Mart\u00ednez-Taboada","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2012.10.023_bib0220","first-page":"S589","article-title":"Results of a randomized controlled study of adalimumab for steroid sparing in patients with giant-cell arteritis (abstract)","volume":"60","author":"Mariette","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2012.10.023_bib0225","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jbspin.2011.09.015","article-title":"Therapeutic approach to giant cell arteritis","volume":"79","author":"Masson","year":"2012","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2012.10.023_bib0230","doi-asserted-by":"crossref","unstructured":"Samson M, Audia S, Fraszczak J, et al. Th1 and Th17 lymphocytes expressing CD161 are implicated in giant cell arteritis and polymyalgia rheumatica pathogenesis. Arthritis Rheum 2012. doi:10.1002\/art.34647 [Epub ahead of print].","DOI":"10.1002\/art.34647"},{"key":"10.1016\/j.jbspin.2012.10.023_bib0235","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1002\/art.34477","article-title":"Inhibition of interleukin-6 function corrects Th17\/Treg cell imbalance in patients with rheumatoid arthritis","volume":"64","author":"Samson","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2012.10.023_bib0240","first-page":"w13156","article-title":"Anti-interleukin 6 receptor therapy as rescue treatment for giant cell arteritis","volume":"141","author":"Seitz","year":"2011","journal-title":"Swiss Med Wkly"},{"key":"10.1016\/j.jbspin.2012.10.023_bib0245","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1136\/ard.2010.149351","article-title":"Rapid induction of remission in large vessel vasculitis by IL-6 blockade. A case series","volume":"70","author":"Beyer","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2012.10.023_bib0250","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1093\/rheumatology\/ker296","article-title":"Tocilizumab: a novel therapy for patients with large-vessel vasculitis","volume":"51","author":"Salvarani","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2012.10.023_bib0255","doi-asserted-by":"crossref","unstructured":"Unizony S, Arias-Urdaneta L, Miloslavsky E, et al. Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica. Arthritis Care Res 2012. doi:10.1002\/acr.21750 [Epub ahead of print].","DOI":"10.1002\/acr.21750"},{"key":"10.1016\/j.jbspin.2012.10.023_bib0260","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1002\/art.20300","article-title":"Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis","volume":"50","author":"Hoffman","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2012.10.023_bib0265","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1093\/rheumatology\/ker380","article-title":"Efficacy and tolerance of infliximab in refractory Takayasu arteritis: French multicentre study","volume":"51","author":"Mekinian","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2012.10.023_bib0270","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1136\/ard.62.6.587","article-title":"Successful treatment of severe rheumatoid vasculitis by infliximab","volume":"62","author":"Unger","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2012.10.023_bib0275","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1136\/ard.2007.081679","article-title":"Anti-tumour necrosis factor treatment in patients with refractory systemic vasculitis associated with rheumatoid arthritis","volume":"67","author":"Pu\u00e9chal","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2012.10.023_bib0280","first-page":"81","article-title":"Rituximab in patients with rheumatoid arthritis and vasculitis-associated cutaneous ulcers","volume":"28","author":"Assmann","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jbspin.2012.10.023_bib0285","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/acr.20689","article-title":"Rituximab therapy for systemic vasculitis associated with rheumatoid arthritis: results from the AutoImmunity and Rituximab Registry","volume":"64","author":"Pu\u00e9chal","year":"2012","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.jbspin.2012.10.023_bib0290","first-page":"S133","article-title":"Successful treatment with humanised anti-interleukin 6 receptor antibody for multidrug-refractory and anti-tumour necrosis factor-resistant systemic rheumatoid vasculitis","volume":"29","author":"Sumida","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jbspin.2012.10.023_bib0295","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1007\/s10165-011-0559-8","article-title":"The rapid efficacy of abatacept in a patient with rheumatoid vasculitis","volume":"22","author":"Fujii","year":"2012","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.jbspin.2012.10.023_bib0300","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0140-6736(83)91685-9","article-title":"Prognosis after immunosuppression of patients with crescentic nephritis requiring dialysis","volume":"1","author":"Hind","year":"1983","journal-title":"Lancet"},{"key":"10.1016\/j.jbspin.2012.10.023_bib0305","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1136\/ard.61.10.922","article-title":"Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab)","volume":"61","author":"Arzoo","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2012.10.023_bib0310","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1056\/NEJMc0800484","article-title":"Anti-glomerular basement membrane disease after alemtuzumab","volume":"359","author":"Clatworthy","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2012.10.023_bib0315","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.3899\/jrheum.120325","article-title":"Tumor necrosis factor-\u03b1 inhibitor-induced antiglomerular basement membrane antibody disease in a patient with rheumatoid arthritis","volume":"39","author":"Nishimura","year":"2012","journal-title":"J Rheumatol"}],"container-title":["Joint Bone Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X12002953?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X12002953?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T04:13:47Z","timestamp":1714709627000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1297319X12002953"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":61,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["S1297319X12002953"],"URL":"https:\/\/doi.org\/10.1016\/j.jbspin.2012.10.023","relation":{},"ISSN":["1297-319X"],"issn-type":[{"value":"1297-319X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7]]}}}